B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Pesce, Silvia ^a   Tabellini, Giovanna ^b   Cantoni, Claudia ^c   Patrizi, Ornella ^b   Coltrini, Daniela ^b   Rampinelli, Fabio ^d   Matta, Jessica ^e,f   Vivier, Eric ^e,f   Moretta, Alessandro ^a   Parolini, Silvia ^b   Marcenaro, Emanuela ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Dipartimento di Cardiologia   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d SPEDALI CIVILI   (Italy)

^e CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^f HÔPITAL DE LA CONCEPTION   (France)

Author keywords

B7 H6; Mechanism of escape; NK cells; NKp30; Ovarian carcinoma

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GRANZYME B; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE ANTIGEN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2A; PERFORIN; PROGRAMMED DEATH 1 LIGAND 1;

ARTICLE; CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEGRANULATION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84954342078     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2014.1001224     Document Type: Article

References (53)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx. doi. org/10. 1126/science. 1198687
2. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx. doi. org/ 10. 1016/S1471-4906(01)02060-9
3. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2:123-8; PMID:11175804; http://dx. doi. org/10. 1038/84219
4. Parolini S, Santoro A, Marcenaro E, LuiniW, Massardi L, Facchetti F, Communi D, Parmentier M, Majorana A, Sironi M et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007; 109:3625-32; PMID:17202316; http://dx. doi. org/10. 1182/blood-2006-08-038844
5. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002; 71:173-83; PMID:11818437
6. Marcenaro E, Della Chiesa M, Ferranti B, Moretta A. In the thick of the fray: NK cells in inflamed tissues. Adv Exp Med Biol 2007; 598:12-9; PMID:17892201; http://dx. doi. org/10. 1007/978-0-387-71767-8_2
7. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619-48; PMID:8717527; http:// dx. doi. org/10. 1146/annurev. immunol. 14. 1. 619
8. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999; 17:875-904; PMID:10358776; http://dx. doi. org/ 10. 1146/annurev. immunol. 17. 1. 875
9. VilchesC, ParhamP. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 2002; 20:217-51; PMID:11861603; http://dx. doi. org/10. 1146/annurev. immunol. 20. 092501. 134942
10. Lopez-Botet M, Llano M, Navarro F, Bellon T. NK cell recognition of non-classical HLA class I molecules. Semin Immunol 2000; 12:109-19; PMID:10764619; http://dx. doi. org/10. 1006/smim. 2000. 0213
11. Lanier LL. NK cell receptors. Annu Rev Immunol 1998; 16:359-93; PMID:9597134; http://dx. doi. org/ 10. 1146/annurev. immunol. 16. 1. 359
12. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197-223; PMID:11244035; http://dx. doi. org/ 10. 1146/annurev. immunol. 19. 1. 197
13. Lanier LL. On guard-activating NK cell receptors. Nat Immunol 2001; 2:23-7; PMID:11135574; http://dx. doi. org/10. 1038/83130
14. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186:1129-36; PMID:9314561; http://dx. doi. org/10. 1084/jem. 186. 7. 1129
15. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998; 188:953-60; PMID:9730896; http://dx. doi. org/10. 1084/jem. 188. 5. 953
16. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complexrestricted tumor cell lysis. J Exp Med 1998; 187:2065-72; PMID:9625766; http://dx. doi. org/10. 1084/ jem. 187. 12. 2065
17. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R, Malaspina A, Parolini S, Moretta L, Moretta A, Biassoni R. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999; 189:787-96; PMID:10049942; http://dx. doi. org/10. 1084/jem. 189. 5. 787
18. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999; 190:1505-16; PMID:10562324; http://dx. doi. org/10. 1084/jem. 190. 10. 1505
19. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26:221-6; PMID:15797513; http://dx. doi. org/ 10. 1016/j. it. 2005. 02. 007
20. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virusinfected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055-60; PMID:11234016; http://dx. doi. org/10. 1038/35059110
21. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, Gazit R, Gonen-Gross T, Hanna J, Nahari E et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005; 6:515-23; PMID:15821739; http://dx. doi. org/ 10. 1038/ni1190
22. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Böll B, Simhadri VL, Borchmann P et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007; 27:965-74; PMID:18055229; http://dx. doi. org/10. 1016/j. immuni. 2007. 10. 010
23. Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, Pogge von Strandmann E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 2008; 3:e3377; PMID:18852879; http://dx. doi. org/10. 1371/journal. pone. 0003377
24. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009; 206:1495-503; PMID:19528259; http://dx. doi. org/10. 1084/jem. 20090681
25. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci 2011; 68:3531-9; PMID:21877119; http://dx. doi. org/ 10. 1007/s00018-011-0802-7
26. Li Y, Wang Q, Mariuzza RA. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J Exp Med 2011; 208:703-14; PMID:21422170; http://dx. doi. org/ 10. 1084/jem. 20102548
27. Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S et al. Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30. Cancer Res 2014; 74:3429-40; PMID:24780758; http://dx. doi. org/10. 1158/0008-5472. CAN-13-3017
28. Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D et al. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 2013; 122:394-404; PMID:23687088; http://dx. doi. org/10. 1182/blood-2013-01-481705
29. Prat J, Oncology F Co G. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124:1-5; PMID:24219974; http://dx. doi. org/10. 1016/j. ijgo. 2013. 10. 001
30. Torres MP, Ponnusamy MP, Lakshmanan I, Batra SK. Immunopathogenesis of ovarian cancer. Minerva medica 2009; 100:385-400; PMID:19910891
31. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. AmJ Surg Pathol 2010; 34:433-43; PMID:20154587; http://dx. doi. org/10. 1097/PAS. 0b013e3181cf3d79
32. Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, Wu L, Butcher EC. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol 2001; 166:6477-82; PMID:11359797; http:// dx. doi. org/10. 4049/jimmunol. 166. 11. 6477
33. Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB, Kalinski P. IL-18-induced CD83+CCR7+ NK helper cells. J Exp Med 2005; 202:941-53; PMID:16203865; http://dx. doi. org/ 10. 1084/jem. 20050128
34. Marcenaro E, Cantoni C, Pesce S, Prato C, Pende D, Agaugue S, Moretta L, Moretta A. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 2009; 114:4108-16; PMID:19749090; http://dx. doi. org/10. 1182/blood-2009-05-222265
35. Marcenaro E, Pesce S, Sivori S, Carlomagno S, Moretta L, Moretta A. KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLA-C2+ DCs or T-cell blasts. Blood 2013; 121:3396-401; PMID:23449637; http://dx. doi. org/10. 1182/blood-2012-09-458752
36. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009; 183:4921-30; PMID:19801517; http:// dx. doi. org/10. 4049/jimmunol. 0901226
37. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007; 122:418-29; PMID:17617155; http://dx. doi. org/ 10. 1111/j. 1365-2567. 2007. 02660. x
38. Wendt K, Wilk E, Buyny S, Buer J, Schmidt RE, Jacobs R. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol 2006; 80:1529-41; PMID:16966385; http://dx. doi. org/10. 1189/jlb. 0306191
39. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999; 29:1656-66; PMID:10359120; http:// dx. doi. org/10. 1002/(SICI)1521-4141(199905) 29:05%3c1656::AID-IMMU1656%3e3. 0. CO;2-1
40. Lowrey DM, Hameed A, Lichtenheld M, Podack ER. Isolation and characterization of cytotoxic granules from human lymphokine (interleukin 2) activated killer cells. Cancer Res 1988; 48:4681-8; PMID:3260817
41. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, Chiang SC, Marcenaro S, Meazza R, Bondzio I et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119:2754-63; PMID:22294731; http://dx. doi. org/10. 1182/blood-2011-08-374199
42. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999; 162:4511-20; PMID:10201989
43. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003; 100:4120-5; PMID:12646700; http://dx. doi. org/10. 1073/pnas. 0730640100
44. Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol ancer 2010; 9:11; PMID:20089172; http://dx. doi. org/10. 1186/1476-4598-9-11
45. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol 2008; 32:1145-57; PMID:18497976; http://dx. doi. org/10. 3892/ijo_32_6_1145
46. Tabellini G, Benassi M, Marcenaro E, Coltrini D, Patrizi O, Ricotta D, Rampinelli F, Moretta A, Parolini S. Primitive neuroectodermal tumor in an ovarian cystic teratoma: natural killer and neuroblastoma cell analysis. Case Rep Oncol 2014; 7:70-8; PMID:24575020; http://dx. doi. org/10. 1159/000357802
47. Funamizu A, Fukui A, Kamoi M, Fuchinoue K, Yokota M, Fukuhara R, Mizunuma H. Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. Am J Reprod Immunol 2014; 71:359-67; PMID:24495049; http:// dx. doi. org/10. 1111/aji. 12206
48. Carlsten M, Bjorkstrom NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007; 67:1317-25; PMID:17283169; http://dx. doi. org/10. 1158/0008-5472. CAN-06-2264
49. Fiegler N, Textor S, Arnold A, Rolle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013; 122:684-93; PMID:23801635; http://dx. doi. org/10. 1182/blood-2013-02-482513
50. Reiners KS, Dassler J, Coch C, Pogge von Strandmann E. Role of exosomes released by dendritic cells and/or by tumor targets: regulation of NK cell plasticity. Front Immunol 2014; 5:91; PMID:24639679; http://dx. doi. org/10. 3389/fimmu. 2014. 00091
51. Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M, Peipp M. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol 2012; 189:5037-46; PMID:23066150; http://dx. doi. org/ 10. 4049/jimmunol. 1201321
52. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx. doi. org/10. 1182/blood. V99. 3. 754
53. Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005; 174:3992-8; PMID:15778356; http://dx. doi. org/10. 4049/jimmunol. 174. 7. 3992